Copper to Zinc Ratio as Disease Biomarker in Neonates with Early-Onset Congenital Infections

Monika Wisniewska 1,†, Malte Cremer 2,†, Lennart Wiehe 1,†, Niels-Peter Becker 1, Eddy Rijntjes 1, Janine Martitz 1, Kostja Renko 1, Christoph Bührer 2 and Lutz Schomburg 1,*

1 Institute for Experimental Endocrinology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany; Monika.Wisniewska@charite.de (M.W.); Lennart.Wiehe@charite.de (L.W.); Niels-Peter.Becker@charite.de (N.-P.B.); Eddy.Rijntjes@charite.de (E.R.); Janine.Martitz@charite.de (J.M.); Kostja.Renko@charite.de (K.R.)
2 Department of Neonatology, Charité-Universitätsmedizin Berlin, Augustenburger Platz 1, CVK, D-13353 Berlin, Germany; Malte.Cremer@charite.de (M.C.); christoph.buehrer@charite.de (C.B.)
* Correspondence: lutz.schomburg@charite.de; Tel.: +49-30-450-524289
† These authors contributed equally.

Received: 24 January 2017; Accepted: 28 March 2017; Published: 30 March 2017

Abstract: Copper (Cu) and zinc (Zn) are essential trace elements for regular development. Acute infections alter their metabolism, while deficiencies increase infection risks. A prospective observational case-control study was conducted with infected \( n = 21 \) and control \( n = 23 \) term and preterm newborns. We analyzed trace element concentrations by X-ray fluorescence, and ceruloplasmin (CP) by Western blot. Median concentration of Cu at birth (day 1) was 522.8 \([387.1–679.7]\) µg/L, and Zn was 1642.4 ± 438.1 µg/L. Cu and Zn correlated positively with gestational age in control newborns. Cu increased in infected newborns from day 1 to day 3. CP correlated positively to Cu levels at birth in both groups and on day 3 in the group of infected neonates. The Cu/Zn ratio was relatively high in infected newborns. Interleukin (IL)-6 concentrations on day 1 were unrelated to Cu, Zn, or the Cu/Zn ratio, whereas C-reactive protein (CRP) levels on day 3 correlated positively to the Cu/Zn -ratio at both day 1 and day 3. We conclude that infections affect the trace element homeostasis in newborns: serum Zn is reduced, while Cu and CP are increased. The Cu/Zn ratio combines both alterations, independent of gestational age. It may, thus, constitute a meaningful diagnostic biomarker for early-onset infections.

Keywords: ceruloplasmin; preterm; C reactive protein; interleukin-6; micronutrient.

1. Introduction

Copper (Cu) and zinc (Zn) are trace elements essential for life and constitute components of numerous enzymes with high importance for survival and function of eukaryotic cells [1–4]. Cu and Zn are necessary for cellular metabolism and the antioxidative defense systems [1–3,5]. The regular fetal development and growth critically depend on both Cu and Zn, especially during the maturation of the nervous system [2,4,5]. Similarly, the maturing immune system relies on these trace elements [2,3,5,6], especially for antibody production (Cu, Zn), function of neutrophils and monocytes (Cu) [6], the viability, proliferation, and differentiation of cells of both the innate and adaptive immune system (Zn), as well as for the maintenance of the skin and mucosal barriers (Zn) [3,6].

Both a deficiency and an excess of Cu or Zn can cause harm, so the homeostasis of both elements is strictly regulated [1–3]. The main source of both micronutrients is dietary intake [1,3]. The absorption from the gastrointestinal tract depends on the nutritional form and the micronutrient status of the subject [4,7]. The cellular homeostasis is controlled by import and export proteins, cytosolic metallochaperones, glutathione, and metallothioneins [1,2,5]. The latter also acts as a dynamic Cu and
Zn pool [3,5]. Around 95% of Cu in blood is bound to liver-derived ceruloplasmin (CP), which is used along with serum Cu concentrations as a biomarker of Cu status [4]. Serum Cu and CP concentrations constitute acute phase reactants [5]. Cu is mainly stored in liver, secreted as Cu-CP complex into blood, and an excess can be eliminated by biliary excretion [1,4]. In contrast to Cu, the protein-mediated transport, storage, and regulated excretion of Zn are more complex and less well understood [3,7].

Cu and Zn deficiencies constitute prevalent and under-diagnosed health risks [1,3]. Neonates and especially preterm infants have a notable risk of Cu and Zn deficiency due to their rapid growth and the concomitant increasing requirement for both micronutrients [4]. On the one hand, Cu or Zn deficiencies impair the immune defense and confer a high susceptibility to infectious diseases [3–6,8]. On the other hand, acute infections cause an increase in serum Cu in the context of an acute phase response [4,9] and a decrease in serum Zn due to a redistribution into liver and other tissues [3,7,10–12]. These two responses to inflammation may feed a vicious cycle of impaired immune defense and higher infection risk, which is of particular importance especially in very vulnerable patients, such as preterm and term neonates with an immature immune system.

Congenital infections and especially neonatal sepsis are a frequent cause for morbidity and mortality of newborns [13–16]. Vertical bacteria transmission from mother to child results in early-onset infections, defined by an onset within 72 h postnatum [16]. The symptoms of a systemic inflammation by newborns are unspecific [13], and the diagnosis is challenging. Isolation of bacteria from blood cultures of neonates is difficult due to the relatively high blood volumes and long incubation times required, and by the initially low bacteria counts in the majority of affected neonates [13,14]. The cytokine interleukin 6 (IL-6) and the acute-phase reactant C-reactive protein (CRP) are important diagnostic markers for early (IL-6) or later (CRP) phases of inflammation [15]. Despite their usefulness, the current clinical algorithm does not provide a satisfying diagnostic specificity in neonates [14], implying that additional biomarkers are needed to facilitate the correct diagnosis and to avoid unnecessary drug administrations. No consented diagnostic and therapeutic guidelines for newborn sepsis have been established. The current therapeutic strategy advocates an early application of an empiric antibiotic treatment if an infection is just suspected [17]. Some antibiotics are applied in terms of an off-label use due to a lack of intervention studies in newborns, raising concerns about their safety [17]. Despite the supportive and antibiotic treatments, congenital infections may still cause long-term complications such as brain damage and neurological sequelae [18].

From animal and clinical studies with adult patients, it is well established that inflammatory cytokines disturb the trace element homeostasis [9]. Furthermore, the Cu/Zn ratio is altered in certain diseases [19–23]. Therefore, we postulated that infections disrupt homeostasis of the trace elements Cu and Zn in neonates.

2. Materials and Methods

2.1. Study Design

The design of this prospective observational case-control study has been described before in the context of the effects of congenital infections on the selenium (Se) status [24]. Briefly, this explorative study was conducted on the neonatology wards of the Charité-Universitätsmedizin Berlin from February 2013 until April 2014, after clearance with the local ethics committee (approval no.: EA2/092/12). Informed written consent was obtained for each neonate enrolled in the study from the legal guardian(s) prior to analysis. Relevant clinical data were extracted from the electronic and traditional paper-based medical files. Trace elements were analyzed using residual plasma samples from routine laboratory evaluations ordered by the attending physician. Hereby, one sample was collected from each neonate (control or infection) at birth (day 1). The 2nd sample was obtained 48 h later (day 3) only from infected neonates.
2.2. Study Population

Neonates were screened for fulfilling the inclusion criteria of early-onset infection according to published recommendations and the diagnostic steps taken [25–27]. In brief, neonates qualifying for the infection group had to exhibit at least one of the following clinical signs: pneumonia, respiratory distress, tachycardia, bradycardia, fever (>38.5 °C), hypothermia (<36.0 °C), irritability, lethargy, hypotonia, poor feeding, increased frequency of apnea, and/or coagulation disorder in combination with laboratory evidence for an inflammation (IL-6 > 100 ng/L, or CRP > 10 mg/L). In neonates with suspected infection, blood cultures were performed prior to antibiotic treatment. Blood cultures were performed with the BacT/ALERT automated system (Organon Teknika, Eppelheim, Germany) in Pedi-BacT pediatric blood culture bottles capable of detecting anaerobic as well as aerobic bacteria. Neonates with suspected early-onset infection were immediately treated with ampicillin and gentamicin for at least 3 days, and a second blood drawing was conducted 48 h later to determine inflammation markers and gentamicin levels. Two residual plasma samples were, thus, available from each of the neonates with suspected infection (day 1 and day 3), and one from the control neonates at time of birth (day 1). The newborns in the control group showed no laboratory evidence for inflammation (IL-6 < 100 ng/L, and/or CRP < 10 mg/L), and were not receiving antibiotic treatment during the hospital stay. Several infants had to be excluded because of birth before 30 weeks of gestation, birth weight below 1000 g, a diagnosed genetic disease, severe congenital malformation, parenteral supplementation with trace elements, or a missing written consent. Details on the neonates enrolled into this study have been published earlier in relation to analyzing their Se status [24] and are provided below (Table 1). Neonates with suspected early-onset infection are summarized as the “infection group” and are denoted as “infected neonates” in this scientific report. However, it needs to be pointed out that a suspected early-onset infection in neonates cannot as safely be diagnosed as in adults for a number of reasons including unspecific symptoms, a higher variability of symptoms, and a very limited amount of blood to be analyzed by laboratory tests and blood culture.

Table 1. Characteristics of the study population, as previously described [24].

| Characteristic | Control Group | Infection Group | p-Value (Two-Sided) |
|---------------|---------------|-----------------|--------------------|
| Participants  | n = 23        | n = 21          | -                  |
| Gestation age [weeks] | 34.9 [33.9–37.1] | 38.4 [35.1–39.8] | 0.003              |
| Term infants | n = 6 (26%)   | n = 13 (62%)    |                    |
| Preterm infants (<37 gestation weeks) | n = 17 (74%) | n = 8 (38%) | 0.003 |
| Birth Weight [g] | 2452.3 ± 694.1 | 3119.7 ± 733.7 |                    |
| Vaginal birth | n = 7 (30%)   | n = 10 (48%)    |                    |
| Twins | n = 7 (30%)   | n = 1 (5%)      |                    |
| Apgar 1 min * | 9.0 [6.0–9.0] | 8.0 [4.5–9.0] | 0.505 |
| Apgar 5 min * | 9.0 [8.0–10.0] | 9.0 [7.5–10.0] | 0.951 |
| Cord arterial pH | 7.25 [7.2–7.29] | 7.23 [7.19–7.3] | 0.655 |
| pH on admission # | 7.33 [7.27–7.38] | 7.33 [7.26–7.37] | 0.673 |
| Base excess on admission ## | −2.15 [−3.75]−(−0.90)] | −2.8 [(−5.32)]−(−1.28)] | 0.283 |
| IL-6 [pg/mL], day 1 | 5.8 [4.2–17.0] | 498.5 [203.6–2523.0] | <0.001 |

* The Apgar score is used to characterize the condition of neonates after birth [28]. The Apgar score evaluates the condition of the neonate 1, 5, and 10 min after birth and guides subsequent interventions. Furthermore, the 5 min Apgar score has been used to predict neurological long-term-outcome. Each of five easily identifiable characteristics—respiration, heart rate, skin color, reflex irritability, and muscle tone—is assessed and assigned a value of 0 to 2. # The blood pH was measured in each neonate immediately after admission to the neonatal ward. ## The base excess refers to an excess or deficit in the amount of base in the blood. A negative base excess reflects an acid/base disturbance caused by the accumulation of lactate acid because of anaerobic glycolysis. IL stands for interleukin.

2.3. Trace Elements

Total plasma Cu and Zn concentrations were determined by total reflection X-ray fluorescence (TXRF) as described in [24]. The method was chosen because of the low sample volume requirements, which is necessary particularly for infants, and prospectively because of the short time needed for
analysis, which is a prerequisite for considering the technique in routine clinical decision-making. Briefly, 10 µL of plasma samples were diluted with 10 µL of a gallium standard solution (f.c. 550 µg/L, Sigma-Aldrich, Steinheim, Germany) and mixed thoroughly. Duplicates of 8 µL each were applied to ultra clean quartz glass carriers, dried at 37 °C and measured using a TXRF spectrometer (S2 PICOFOX, Bruker nano GmbH, Berlin, Germany) as described in [29]. The inter-assay coefficient of variation (CV) was less than 10% for both Cu and Zn.

2.4. Ceruloplasmin

Western blot analysis was performed for assessment of plasma CP levels. Three Western blots were prepared containing plasma samples from neonates of the control group along with samples from infected neonates. An additional Western blot was prepared with samples from the group of infected neonates that were pre-selected with respect to the CRP levels. Plasma was diluted in ultrapure H₂O (Biochrom AG, Berlin, Germany) and 4x sample buffer (200 mM Tris-HCl, pH 7.5, 50% glycerin, 4% SDS, 0.04% bromophenol blue, and 125 mM DTT). Plasma proteins were size-fractionated by sodium dodecyl (lauryl) sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently transferred onto nitrocellulose membranes by semi-dry blotting (Optitran, Schleicher & Schuell, Dassel, Germany). Antibodies against CP (1:2000 dilution, ab19171, Abcam, Cambridge, UK) were used and bands visualized by chemiluminescence (Western-Bright Substrate Sirius, Biozym Scientific, Oldendorf, Germany) using the Fluor Chem FC2 detection system (Biozym Scientific). Quantification of Western blot signals was achieved by using the Java-based image processing program ImageJ (NIH, Bethesda, MD, USA).

2.5. Interleukin 6 and C-reactive Protein

The IL-6 and CRP values were measured by Labor Berlin, Charité Vivantes GmbH, Germany, by standard laboratory analyses as described earlier [24]. Briefly, IL-6 was measured by an electro-chemical luminescence immunoassay and CRP was determined by a turbidometric assay (COBAS 8000 or COBAS 6000; Roche Diagnostics, Mannheim, Germany).

2.6. Statistical Analysis

Statistical analysis was performed with the Statistical Package for the Social Sciences (SPSS Statistics 21®, IBM, Chicago, IL, USA) and GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA). Normal distribution of values was assessed by the Shapiro-Wilk test. A two-tailed T-test for unpaired or paired variables and the bivariate Pearson correlation test were used for normally distributed values. For not-normally distributed variables, the Mann-Whitney-U-test, the Wilcoxon-test, and the Spearman’s correlation test were used. The quantified Western blot signals were analyzed using nonparametric tests (Mann-Whitney-U-Test, the Wilcoxon-Test, and the Spearman’s correlation test). Linear regression analysis was conducted to specify associations of variables. Multiple logistic regression was performed to evaluate the results in consideration of relevant confounders. Odds ratios where calculated to examine the quality of the Cu/Zn ratio as a biomarker. The results were considered as statistically significant when the p-value was less than 0.05, and differences are marked as follows: p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***).. Parametric data are represented as means ± standard deviation (SD) or medians and interquartile range (IQR); median [IQR].

3. Results

3.1. Cu and Zn Status at Day of Birth in Control and Infected Newborns

Out of 108 newborns, a total of 72 neonates qualified for analysis. Written informed consent was provided for 44 of the samples, of which 23 fulfilled criteria for the control and 21 for the infection group (Table 1). Newborns in the control group had on average a lower gestational age, and lower birth weight. There were more preterm infants (<37 weeks of gestation) in the non-infection control
There was no significant difference between the control and the infection group. The distribution of plasma Cu concentrations was more heterogeneous in the infection group as compared to that of the control group (Table 2), whereas the newborns in the control group were not displaying any of these signs in combination with laboratory evidence of an inflammation. None of the neonates in the infection group had a positive blood culture. None of the infected or control children had severe thrombocytopenia or leukocytopenia, or displayed any specific signs for an infection with toxoplasma gondii, rubella virus, cytomegalovirus, or herpes simplex virus 1 or 2 (TORCH). No mother had a history of TORCH infection during pregnancy.

Table 2. Clinical characteristics of the neonates with suspected early-onset infection (n = 21). IL stands for interleukin; IRQ stands for interquartile range; CRP stands for C-reactive protein; SD stands for standard deviation.

| Clinical Characteristics | n = 19 | n = 6 | n = 2 | n = 3 | n = 0 | 498.5 [203.6–2523.0] | 12.1 ± 7.8 | 5.0 [3.0–5.0] |
|--------------------------|-------|-------|-------|-------|-------|----------------------|-------------|-------------|
| Pneumonia/Respiratory Distress |       |       |       |       |       |                      |             |             |
| Tachycardia/bradycardia   |       |       |       |       |       |                      |             |             |
| Fever/hypothermia         |       |       |       |       |       |                      |             |             |
| Irritability/lethargy     |       |       |       |       |       |                      |             |             |
| Coagulation disorder      |       |       |       |       |       |                      |             |             |
| IL-6 [ng/L], day 1 (median [IQR]) |       |       |       |       |       |                      |             |             |
| CRP [mg/L], day 3, (mean ± SD) |       |       |       |       |       |                      |             |             |
| Antibiotic treatment [days] (median [IQR]) |       |       |       |       |       |                      |             |             |

The median concentration of plasma Cu of all neonates on day 1 was 522.8 [387.1–679.7] µg/L. There was no significant difference between the control and the infection group. The distribution of plasma Cu concentrations was more heterogeneous in the infection group as compared to that of the control group (Figure 1A). Zn concentrations were normally distributed in both groups of newborns, and were higher in the control group as compared to that of the infection group (1804.6 ± 377.0 vs. 1464.8 ± 439.3 µg/L, p = 0.009) (Figure 1B). When separating the newborns according to infection and gestational age, Zn levels were significantly lower in the infected term infants as compared to that of the control term infants (1430.3 ± 374.4 vs. 2021.0 ± 488.7 µg/L; p = 0.01), but there was no difference in Zn concentration between the infected vs. control preterm neonates.

Figure 1. Plasma Cu and Zn in control and infected neonates. (A) The Cu concentrations in plasma are not significantly different between the groups of control (n = 23) and infected (n = 21) neonates on the day of birth (day 1); Mann-Whitney U Test: U = 184; Z = −1.351; p = 0.177; (B) Infected neonates exhibit significantly lower Zn concentrations as compared to that of control neonates; T-Test (two-sided, unpaired), **: p < 0.01.
3.2. Cu and CP in Relation to Gestational Age and Infection

Plasma Cu concentrations increased with gestational age in the neonates (Figure 2A). When comparing all samples, plasma Cu concentrations were higher in term neonates as compared to that of preterm neonates (715.8 ± 254.0 vs. 461.4 ± 160.5 μg/L; \( p = 0.001 \)) (Figure 2B). There was a significant positive correlation of gestational age and plasma Cu concentrations in the group of control neonates (Figure 2C), but not in the group of infected neonates (Figure 2D). There were no significant differences of the plasma Cu between female and male neonates in the control (491.6 ± 144.1 μg/L (males) vs. 572.0 ± 247.5 μg/L (females); \( p = 0.332 \)) or in the infection group (494.8 ± 195.1 μg/L (males) vs. 681.1 ± 299.7 μg/L (females); \( p = 0.178 \)), when corrected for gestational age and sex.

![Figure 2](image_url)  
**Figure 2.** Association of plasma Cu at birth with gestational age. (A) In the combined (infection plus control) group, plasma Cu at birth (day 1) correlates positively with gestational age; (B) In the combined (infection plus control) group, mean Cu concentration at day 1 is higher in term as compared to that in preterm (<37 gestational weeks) neonates; \( n = 44 \), T-Test (two-sided, unpaired), \( p = 0.001 \); (C) In the control group, plasma Cu increases with gestational age; (D) In infected neonates, there is no significant association of plasma Cu with gestational age. The shaded area (---) indicates pregnancy length until term, and includes the preterm neonates (<37 weeks of gestation); \( \rho \): Spearman’s rank correlation coefficient; \( r \): Pearson correlation coefficient; \( \beta \): standardised regression coefficient; **: \( p < 0.01 \).

Ceruloplasmin (CP) in plasma is an established transport protein for Cu. In order to test whether an early-onset infection affects plasma CP and Cu levels alike, both biomarkers were determined from plasma of infected and control neonates. Western blot analysis detected a single band for CP at the expected size of 130 kDa (Figure 3A). Relative CP units were determined by quantification of the detected signals and showed a significant correlation to the Cu concentrations both at birth (day 1) (Figure 3B) and at day 3 (Figure 3C).
The acute phase protein CRP is determined as late biomarker of neonatal infection. CRP levels increased in infected newborns from day 1 to day 3 (Figure 4A). Plasma Cu concentrations increased in infected newborns from day 1 to day 3 (Figure 4B). The acute phase protein CRP is determined as late biomarker of neonatal infection. CRP on day 3 was positively associated with plasma Cu concentrations both on day 1 (r = 0.720, p < 0.001, β = 0.720) and on day 3 (Figure 4C). A similar positive correlation was detected between plasma CP and CRP concentrations (Figure 4D). The CP detected in plasma of infected newborns ran as a single protein of the expected size, and it was relatively abundant in samples with elevated CRP levels (Figure 4E).
3.3. Associations of Zn with Gestational Age, Birth Weight, and Infection

Plasma Zn concentrations correlated positively to gestational age in control neonates (Figure 5A). In comparison, no significant correlation was observed in the group of infected neonates (Figure 5B). Similarly, plasma Zn concentrations were positively correlated with birth weight in the group of controls (Figure 5C) but not in infected neonates (Figure 5D). There were no significant differences of the plasma Zn concentrations between female and male neonates either in the control group (1739.4 ± 316.2 μg/L (males) vs. 1926.8 ± 469.7 μg/L (females); p = 0.266) or in the infection group (1308.9 ± 234.3 μg/L (males) vs. 1527.2 ± 491.4 μg/L (females); p = 0.316). The diagnostic markers of inflammation determined in the group of infected neonates, i.e., IL-6 on day 1 and CRP on day 3, were not associated with the plasma Zn concentrations at day 1 (Figure 5E) or at day 3 (Figure 5F).
Figure 5. Associations of plasma Zn with gestational age, birth weight, and infection markers. (A) There is a positive correlation between plasma Zn and gestational age in the control group; (B) In infected neonates, plasma Zn and gestational age are not related; (C) Similarly, plasma Zn is positively associated with birth weight in the control group; (D) but not in the group of infected neonates; (E) There is neither an association of plasma Zn concentrations with the early marker of infection, i.e., IL-6; (F) nor with the late marker CRP. The shaded area (■) indicates the preterm neonates (<37 weeks of gestation); ρ: Spearman’s rank correlation coefficient; r: Pearson correlation coefficient; β: standardised regression coefficient; *: p < 0.05; **: p < 0.01.

3.4. Cu/Zn Ratio

In our quest for a more robust parameter, which may complement the current diagnostic tools for suspected early-onset infections, the Cu/Zn ratios were calculated. This ratio was significantly higher in the infection group as compared to that of the control group of neonates (Figure 6A). In infected neonates, there was no association of the Cu/Zn ratio with the IL-6 levels on day 1 (Figure 6B). However, the CRP levels determined at day 3 in infected neonates showed a positive correlation to both the Cu/Zn ratios at the day of birth (day 1) (Figure 6C) and at day 3 (Figure 6D). Furthermore, the plasma Cu/Zn ratio was correlated with gestational age in the control group (ρ = 0.417*, p = 0.048) but not in the infection group (r = 0.332, p = 0.141).
which indicates a high Cu/Zn ratio (>50th-percentile) has during infection. As the plasma concentrations of these two trace elements are regulated in opposite show relatively low plasma Zn concentrations at birth, and develop elevated plasma Cu concentrations gestational age in control newborns, and that this correlation is lost in infection. Infected neonates in preterm and term neonates. Our results indicate that both trace elements increase in plasma with

4. Discussion

To verify the reliability of the Cu/Zn ratio as a biomarker for early-onset infection considering the different distribution of gestational age between the groups, we conducted a multinomial logistic regression with gestational age as a covariate. The Odds Ratio for the Cu/Zn ratio (day 1) was 9.067 (95% confidence interval 2.306–35.650), which indicates a high Cu/Zn ratio (>50th-percentile) has higher odds for infection than those in the <50th-percentile-group (Table 3).

Table 3. Association of Cu/Zn ratio and infection adjusted for gestational age by multiple logistic regression analysis. CI: confidence interval.

|                           | Significance | Odds Ratio | 95% CI            |
|---------------------------|--------------|------------|-------------------|
| Gestational age           | 0.079        | 1.310      | 0.969–1.770       |
| Cu/Zn ratio               | 0.034        | 164.224    | 1.457–18,506.693  |

4. Discussion

In this study, we evaluate the infection-related differences in plasma Cu and Zn concentrations in preterm and term neonates. Our results indicate that both trace elements increase in plasma with gestational age in control newborns, and that this correlation is lost in infection. Infected neonates show relatively low plasma Zn concentrations at birth, and develop elevated plasma Cu concentrations during infection. As the plasma concentrations of these two trace elements are regulated in opposite
directions by infection, we speculated that the Cu/Zn ratio may provide a more robust marker of early-onset infection than either value alone. Our study indicates that the Cu/Zn ratio correlates to the CRP levels determined at day 3 as the established biomarker of infection. Interestingly, this correlation is already shown at day 1. It remains to be tested if it could be of value for the diagnosis of early-onset infections. The Cu/Zn ratio at day 1 may already reflect the severity and predict the potential course of the infection, which then becomes detected later by the elevated CRP levels determined at day 3. It may, thus, constitute a helpful early prognostic biomarker of early-onset infection in term and preterm neonates.

There is evidence that preterm neonates are at especially high risk for Cu and Zn deficiency [4,30]. This notion is supported by previous studies reporting that the maternal Cu levels rise with the length of gestation [31]. Consistent with former findings in neonates [32], the Cu concentrations of the infants in our study were lower, and Zn was higher than in adults (adult reference intervals according to [11]; Cu; 10–22 µM, i.e., 635.5–1398.0 µg/L, and Zn; 12–18 µM, i.e., 784.6–1176.8 µg/L). Our data are in line with previous studies in young children, especially with respect to an increase in plasma Cu levels upon infection [33]. Notably, also in preterm and term infants, a tight correlation of plasma Cu concentrations and plasma CP is reported [34]. These data along with our findings support the concept that plasma CP may serve as a surrogate marker of plasma Cu concentrations in children. This relation offers the option for bed-side testing of the Cu status by immunological assay procedures, as recently demonstrated by using quantum dots for fast CP quantification [35]. Unfortunately, no reliable protein biomarker of plasma Zn status is yet at hand, which would enable a fast multiplex bed-side quantification of the Cu/Zn ratio via these surrogate protein biomarkers that can be detected by point-of-care technologies.

Importantly, the inverse regulation of plasma Cu and Zn is a well-established characteristic of infections, and the Cu/Zn ratio has been proven of diagnostic value in a number of human disorders, including pediatric infectious diseases, such as giardiasis or amebiasis [20] and tuberculosis [23,36]. Furthermore, the diagnostic value of the Cu/Zn ratio as a disease marker was also shown in autism, attention-deficit hyperactivity disorder, hypertension, inflammatory, as well as neoplastic diseases [33,37–39]. The quotient was also described as a potential biomarker of inflammation and nutritional status as well as a mortality predictor in elderly people [40], and as a variable correlating with inflammation, disrupted immune system, and an increased oxidative stress in peritoneal dialysis [41]. Our data indicate that the Cu/Zn ratio may also be of diagnostic value in neonates with suspected infection, as it was associated with severity of inflammation at an early time point while being independent of gestational age.

4.1. Early-Onset Congenital Infections as Disruptors of the Trace Element Homeostasis

We found significantly lower plasma Zn concentrations in infected neonates compared with that of the control group, which is congruent with former findings in children, adults, and animals suffering from an acute inflammation and/or critical illness [3,7,10,11,42]. However, Zn levels were not associated with the early inflammation marker IL-6 or with the late acute phase reactant CRP. This lack of stringent interrelation is in line with studies in adults, where there are only marginal correlations of serum Zn with markers of inflammation [43]. This may indicate that low plasma Zn may not reflect the severity of the inflammation, i.e., it may not be directly regulated by the cytokines released in response to infection. However, in other studies, a respective correlation of plasma Zn with inflammation markers in critically ill children and adults has been reported [11,44]. The lower Zn levels in our infected neonates may, thus, not necessarily be the consequence of the inflammation, but potentially a risk factor for infection [8]. However, this hypothesis needs to be tested in other clinical trials, as our analysis is an observational study and not designed to identify causal relationships.

The Cu levels increased with gestational age. In general, the fetal hepatic tissue does not efficiently support an incorporation of Cu into the CP apoenzyme [32]. Thus, the increasing Cu levels with age may reflect the functional maturation of the liver. Due to ethical reasons, only residual plasma samples
were available from infected neonates at day 3 but not from control neonates. Such an analysis would shed light on the relative importance of age and infection for the rising Cu concentrations observed in the study. Moreover, the diagnosis of infection in the newborns was based on clinical symptoms in combination with laboratory evidence for an inflammation, and not on positive blood cultures or additional laboratory analysis, which constitutes a general shortcoming of our study.

4.2. The Cu/Zn Ratio as a Potential Biomarker of Early-Onset Congenital Infections

The concentrations of plasma Cu or Zn considered separately did not qualify as useful biomarkers of early-onset infection. The correlation of Cu on day 1 with CRP on day 3 seems to impart a predictive value to the trace element, and the association on day 3 implicates its potential as a clinical marker of disease course. However, Cu levels were not significantly different between control and infected subjects at birth. The strong positive association of CP and CRP on day 3 suggests that CP is related to the severity of infection. CP is described as a positive acute phase reactant in adults [4,9]. However, it decreases with time during increasing severity of the inflammation in adults [11,45], suggesting that it does not steadily correlate to infection severity. Zn levels were significantly lower in infected neonates compared with that of the control group at birth. However, Zn neither correlated with IL-6 on day 1, nor with CRP on day 3. Considering these interactions, Zn alone does not seem to quality as an appropriate infection marker in neonates.

Nevertheless, the Cu/Zn ratio appears to provide additional information on the possible infection of newborns. This notion needs to be tested in prospective trials with a sufficient number of neonates, as both the infection and control groups were relatively small in our pilot study.

5. Conclusions

Infection as well as inflammation can affect the trace element homeostasis in newborns. Infected neonates may develop increased plasma Cu concentrations and display a relative plasma Zn deficit. The Cu/Zn ratio may thus constitute a useful biomarker of early-onset infection in neonates with some relation to the clinical course.

Acknowledgments: We express our gratitude to all parents and children who took part in this study and to our clinical colleagues in the Department of Neonatology, Charité-Universitätsmedizin Berlin, Germany. This work was supported by DFG Grants RE3038/1–1 (to Kostja Renko) and Scho849/4–1 (to Lutz Schomburg) and an Elsa-Neumann stipend from the City of Berlin (to Janine Martitz).

Author Contributions: Monika Wisniewska, Malte Cremer, Lennart Wiehe, Niels-Peter Becker, Christoph Bührer, and Lutz Schomburg formulated the research question and designed the study. Monika Wisniewska, Lennart Wiehe, Niels-Peter Becker, Eddy Rijntjes, Janine Martitz, and Kostja Renko conducted the experimental analyses. All authors contributed to the statistical analysis and interpretation of the data. All authors contributed to writing and editing the manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Stern, B.R. Essentiality and toxicity in copper health risk assessment: Overview, update and regulatory considerations. *J. Toxicol. Environ. Health Part A* 2010, 73, 114–127. [CrossRef] [PubMed]
2. Chasapis, C.T.; Loutsidou, A.C.; Spiliopoulou, C.A.; Stefanidou, M.E. Zinc and human health: An update. *Arch. Toxicol.* 2012, 86, 521–534. [CrossRef] [PubMed]
3. Bonaventura, P.; Benedetti, G.; Albarede, F.; Miossec, P. Zinc and its role in immunity and inflammation. *Autoimmun. Rev.* 2015, 14, 277–285. [CrossRef] [PubMed]
4. De Romana, D.L.; Olivares, M.; Uauy, R.; Araya, M. Risks and benefits of copper in light of new insights of copper homeostasis. *J. Trace Elem. Med. Biol.* 2011, 25, 3–13. [CrossRef] [PubMed]
5. Uriu-Adams, J.Y.; Keen, C.L. Copper, oxidative stress, and human health. *Mol. Asp. Med.* 2005, 26, 268–298. [CrossRef] [PubMed]
6. Maggini, S.; Wintergerst, E.S.; Beveridge, S.; Hornig, D.H. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. Br. J. Nutr. 2007, 98 (Suppl. S1), 29–35. [CrossRef] [PubMed]

7. Rink, L.; Gabriel, P. Zinc and the immune system. Proc. Nutr. Soc. 2000, 59, 541–552. [CrossRef] [PubMed]

8. Krebs, N.F.; Miller, L.V.; Hambidge, K.M. Zinc deficiency in infants and children: A review of its complex and synergistic interactions. Paediatr. Int. Child Health 2014, 34, 279–288. [CrossRef] [PubMed]

9. Milanino, R.; Marrella, M.; Gasperini, R.; Pasqualicchio, M.; Velo, G. Copper and zinc body levels in inflammation: An overview of the data obtained from animal and human studies. Agents Actions 1993, 39, 195–209. [CrossRef] [PubMed]

10. Besecker, B.Y.; Exline, M.C.; Hollyfield, J.; Phillips, G.; Disilvestro, R.A.; Wewers, M.D.; Knoell, D.L. A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. Am. J. Clin. Nutr. 2011, 93, 1356–1364. [CrossRef] [PubMed]

11. Stefanowicz, F.; Gashut, R.A.; Talwar, D.; Duncan, A.; Beulshausen, J.F.; McMillan, D.C.; Kinsella, J. Assessment of plasma and red cell trace element concentrations, disease severity, and outcome in patients with critical illness. J. Crit. Care 2014, 29, 214–218. [CrossRef] [PubMed]

12. Shah, B.A.; Padbury, J.F. Neonatal sepsis: An old problem with new insights. Virulence 2014, 5, 170–178. [CrossRef] [PubMed]

13. Molyneux, E.; Gest, A. Neonatal sepsis: An old issue needing new answers. Lancet Infect. Dis. 2015, 15, 503–505. [CrossRef]

14. Hedegaard, S.S.; Wisborg, K.; Hvas, A.M. Diagnostic utility of biomarkers for neonatal sepsis—a systematic review. Infect. Dis. 2015, 47, 117–124. [CrossRef] [PubMed]

15. Raimondi, F.; Ferrara, T.; Maffucci, R.; Milite, P.; Del Buono, D.; Santoro, P.; Grimaldi, L.C. Neonatal sepsis: A difficult diagnostic challenge. Clin. Biochem. 2011, 44, 463–464. [CrossRef] [PubMed]

16. Shah, B.A.; Padbury, J.F. Neonatal sepsis: An old problem with new insights. Virulence 2014, 5, 170–178. [CrossRef] [PubMed]

17. Bajetic, M.; Spasic, S.; Spasojevic, I. Redox therapy in neonatal sepsis: Reasons, targets, strategy, and agents. Shock 2014, 42, 179–184. [CrossRef] [PubMed]

18. Alshaikh, B.; Yusuf, K.; Sauve, R. Neurodevelopmental outcomes of very low birth weight infants with neonatal sepsis: Systematic review and meta-analysis. J. Perinatol. 2013, 33, 558–564. [CrossRef] [PubMed]

19. Karahan, S.C.; Deger, O.; Orem, A.; Ucar, F.; Erem, C.; Alver, A.; Onder, E. The effects of impaired trace element status on polymorphonuclear leukocyte activation in the development of vascular complications in type 2 diabetes mellitus. Clin. Chem. Lab. Med. 2001, 39, 109–115. [CrossRef] [PubMed]

20. Karakas, Z.; Demirel, N.; Tarackioglu, M.; Mete, N. Serum zinc and copper levels in southeastern turkish children with giardiasis or amebiasis. Biol. Trace Elem. Res. 2001, 84, 11–18. [CrossRef]

21. Oyama, T.; Matsuura, K.; Kawamoto, T.; Mitsuhashi, T.; Shirakusa, T.; Kodama, Y. Efficiency of serum copper/zinc ratio for differential diagnosis of patients with and without lung cancer. Biol. Trace Elem. Res. 1994, 42, 115–127. [CrossRef] [PubMed]

22. Donma, M.M.; Donma, O.; Tas, M.A. Hair zinc and copper concentrations and zinc: Copper ratios in pediatric malignancies and healthy children from southeastern turkey. Biol. Trace Elem. Res. 1993, 36, 51–63. [CrossRef] [PubMed]

23. Luterotti, S.; Kordic, T.V.; Letoja, I.Z.; Dodig, S. Contribution to diagnostics/prognostics of tuberculosis in children. II. Indicative value of metal ions and biochemical parameters in serum. Acta Pharm. 2015, 65, 321–329. [CrossRef] [PubMed]

24. Wiehe, L.; Cremer, M.; Wisniewska, M.; Becker, N.P.; Rijntjes, E.; Martitz, J.; Hybsier, S.; Renko, K.; Buhrer, C.; Schomburg, L. Selenium status in neonates with connatal infection. Br. J. Nutr. 2016, 116, 504–513. [CrossRef] [PubMed]

25. Young Infants Clinical Signs Study Group. Clinical signs that predict severe illness in children under age 2 months: A multicentre study. Lancet 2008, 371, 135–142.

26. Goldstein, B.; Giroir, B.; Randolph, A.; International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. Pediatr. Crit. Care Med. 2005, 6, 2–8. [CrossRef] [PubMed]
27. Dollner, H.; Vatten, L.; Austgulen, R. Early diagnostic markers for neonatal sepsis: Comparing c-reactive protein, interleukin-6, soluble tumour necrosis factor receptors and soluble adhesion molecules. *J. Clin. Epidemiol.* 2001, 54, 1251–1257. [CrossRef]

28. Apgar, V. A proposal for a new method of evaluation of the newborn infant. *Curr. Res. Anesth. Analg.* 1953, 32, 260–267. [CrossRef] [PubMed]

29. Stosnach, H. Environmental trace-element analysis using a benchtop total reflection X-ray fluorescence spectrometer. *Anal. Sci.* 2005, 21, 873–876. [CrossRef] [PubMed]

30. Lombeck, I.; Fuchs, A. Zinc and copper in infants fed breast-milk or different formula. *Eur. J. Pediatr.* 1994, 153, 770–776. [CrossRef] [PubMed]

31. Zhang, Z.; Yuan, E.; Liu, J.; Lou, X.; Jia, L.; Li, X.; Zhang, L. Gestational age-specific reference intervals for blood copper, zinc, calcium, magnesium, iron, lead, and cadmium during normal pregnancy. *Clin. Biochem.* 2013, 46, 777–780. [CrossRef] [PubMed]

32. Salmenpera, L.; Perheentupa, J.; Pakarinen, P.; Siimes, M.A. Cu nutrition in infants during prolonged exclusive breast-feeding: Low intake but rising serum concentrations of cu and ceruloplasmin. *Am. J. Clin. Nutr.* 1986, 43, 251–257. [PubMed]

33. Shenkin, A. Trace elements and inflammatory response: Implications for nutritional support. *Nutrition* 1995, 11, 100–105. [PubMed]

34. Koo, W.W.K.; Succop, P.; Hambidge, K.M. Sequential concentrations of copper and ceruloplasmin in serum from preterm infants with rickets and fractures. *Clin. Chem.* 1991, 37, 556–559. [PubMed]

35. Li, Z.H.; Wang, Y.; Wang, J.; Tang, Z.W.; Pounds, J.G.; Lin, Y.H. Rapid and sensitive detection of protein biomarker using a portable fluorescence biosensor based on quantum dots and a lateral flow test strip. *Anal. Chem.* 2010, 82, 7008–7014. [CrossRef] [PubMed]

36. Mohan, G.; Kulshreshtha, S.; Dayal, R.; Singh, M.; Sharma, P. Effect of therapy on serum zinc and copper in primary complex of children. *Biol. Trace Elem. Res.* 2004, 100, 117–123. [CrossRef]

37. Canatan, H.; Bakan, I.; Akbulut, M.; Halifeoglu, I.; Cikim, G.; Baydas, G.; Kilic, N. Relationship among levels of leptin and zinc, copper, and zinc/copper ratio in plasma of patients with essential hypertension and healthy normotensive subjects. *Biol. Trace Elem. Res.* 2004, 100, 117–123. [CrossRef]

38. Faber, S.; Zinn, G.M.; Kern, J.C., 2nd; Kingston, H.M. The plasma zinc/sodium copper ratio as a biomarker in children with autism spectrum disorders. *Biomarkers* 2009, 14, 171–180. [CrossRef] [PubMed]

39. Buntzel, J.; Glatzel, M.; Micke, O.; Mucke, R.; Schonekaes, K.; Bruns, F.; Frohlich, D. The copper-zinc-ratio as marker of tumor activity in head and neck cancer? *Strahlenther. Onkol.* 2005, 181, 122.

40. Malavolta, M.; Giacconi, R.; Piacenza, F.; Santarelli, L.; Cipriano, C.; Costarelli, L.; Tesei, S.; Pierpaoli, S.; Basso, A.; Galeazzi, R; et al. Plasma copper/zinc ratio: An inflammatory/nutritional biomarker as predictor of all-cause mortality in elderly population. *Biogerontology* 2010, 11, 309–319. [CrossRef] [PubMed]

41. Guo, C.H.; Chen, P.C.; Yeh, M.S.; Hsiung, D.Y.; Wang, C.L. Cu/Zn ratios are associated with nutritional status, oxidative stress, inflammation, and immune abnormalities in patients on peritoneal dialysis. *Clin. Biochem.* 2011, 44, 275–280. [CrossRef] [PubMed]

42. Cvijanovich, N.Z.; King, J.C.; Flori, H.R.; Gildengorin, G.; Vinks, A.A.; Wong, H.R. A safety and dose escalation study of intravenous zinc supplementation in pediatric critical illness. *JPEN* 2016, 40, 860–868. [CrossRef] [PubMed]

43. Jung, S.; Kim, M.K.; Choi, B.Y. The relationship between zinc status and inflammatory marker levels in rural Korean adults aged 40 and older. *PLoS ONE* 2015, 10, e0130016. [CrossRef] [PubMed]

44. Cvijanovich, N.Z.; King, J.C.; Flori, H.R.; Gildengorin, G.; Vinks, A.A.; Wong, H.R. Zinc homeostasis in pediatric critical illness. *Pediatr. Crit. Care Med.* 2009, 10, 29–34. [CrossRef] [PubMed]

45. Duncan, A.; Talwar, D.; McMillan, D.C.; Stefanowicz, F.; O’Reilly, D.S. Quantitative data on the magnitude of the systemic inflammatory response and its effect on micronutrient status based on plasma measurements. *Am. J. Clin. Nutr.* 2012, 95, 64–71. [CrossRef] [PubMed]